PRAZIQUANTEL

Praziquantel increases calcium permeability in parasitic worms, causing rapid spastic paralysis and tegument damage, leading to elimination. It is used for schistosomiasis and tapeworm infections. Benefits include high cure rates with short courses. Side effects include abdominal pain, dizziness, headache, fatigue, and allergic or inflammatory reactions related to parasite death.

SKU: 1464c945a3c5 Category: Tag:

Product Description


Mechanism of Action

PRAZIQUANTEL (ID 27203) exhibits a complex, multi‑pathway biochemical activity profile influencing enzymatic cascades, receptor‑mediated signalling networks, mitochondrial respiration, oxidative‑stress balance, intracellular ion regulation, membrane‑potential stability and transcription‑factor activation. Its structural framework suggests potential interactions with catalytic residues, allosteric regulatory pockets, membrane‑embedded receptor complexes and intracellular signalling scaffolds. These interactions may modulate phosphorylation patterns, second‑messenger systems (Ca²⁺, IP₃, DAG, cAMP), ATP turnover, ROS equilibrium, cytoskeletal organisation and organelle stress‑response thresholds.

Depending on dosing, PRAZIQUANTEL can influence metabolic flux routing, alter chromatin accessibility, modify vesicular transport, reshape mitochondrial output and regulate transcriptional clusters associated with cellular survival, apoptosis, autophagy, inflammatory signalling and metabolic adaptation. This multi‑axis behaviour supports its wide applicability in advanced biochemical and pharmacodynamic research systems.

Benefits and Advantages

The compound is widely utilised for:

  • Receptor–ligand interaction analysis and affinity modelling
  • Enzyme‑kinetic profiling and catalytic‑pathway reconstruction
  • Mitochondrial‑bioenergetics assays and oxidative‑stress evaluation
  • Multi‑omics integration (transcriptomics, proteomics, metabolomics, phosphoproteomics)
  • Cytoskeletal and membrane‑dynamics studies
  • Apoptosis, necroptosis, autophagy and ferroptosis pathway characterisation
  • SAR (structure–activity relationship) development and molecular screening
  • Pharmacodynamic modelling and mechanistic dose–response simulations

Side Effects and Risks

Potential laboratory‑observed risks include:

  • Excessive ROS production and oxidative imbalance
  • Mitochondrial hyperactivation or suppression of electron‑transport complexes
  • Ion‑channel dysregulation (Na⁺, K⁺, Ca²⁺)
  • Unintended receptor cross‑talk or inhibition
  • Cytoskeletal destabilisation and membrane‑integrity compromise
  • Dose‑dependent cytotoxicity or activation of apoptotic/autophagic pathways
  • Transcriptional or epigenetic instability
  • Upregulation of inflammatory cascades (NF‑κB, JNK, p38 MAPK)

Use exclusively within controlled laboratory conditions and according to strict biosafety standards.

Datasheet


Molecular Formula

C19H24N2O2

Molecular Weight

312.4 g/mol

CAS Number

55268-74-1

Storage Condition

Store in a cool, dry place. Keep container tightly closed. Protect from moisture and light.

Solubility

Solubility depends on solvent and conditions (e.g., pH). Please contact us for solvent-specific guidance.

Purity

Purity information is available upon request (COA).

Synonym

praziquantel; 55268-74-1; Biltricide; Droncit; Embay 8440

IUPAC/Chemical Name

2-(cyclohexanecarbonyl)-3,6,7,11b-tetrahydro-1H-pyrazino[2,1-a]isoquinolin-4-one

InChl Key

FSVJFNAIGNNGKK-UHFFFAOYSA-N

InChl Code

InChI=1S/C19H24N2O2/c22-18-13-20(19(23)15-7-2-1-3-8-15)12-17-16-9-5-4-6-14(16)10-11-21(17)18/h4-6,9,15,17H,1-3,7-8,10-13H2

References

https://pubchem.ncbi.nlm.nih.gov/compound/4891;

3D Conformer.

(Click, turn or enlarge)

Download our GMP API Product List.

MedicaPharma is an EU-based supplier of GMP-certified APIs that serves leading healthcare institutions and research organizations.
Click here to download our full API product list.

Download